The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Abuchowski, A., van Es, T., Palczuk, N. C., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40291-2 · Cited by 1,358
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes
Cerutti, A., Cols, M., & Puga, I. (2013) · Nature Reviews Immunology · doi:10.1038/nri3383 · Cited by 777
Large unilamellar liposomes with low uptake into the reticuloendothelial system
Allen, T. M., & Chonn, A. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80506-9 · Cited by 729
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
CRIg: A Macrophage Complement Receptor Required for Phagocytosis of Circulating Pathogens
Helmy, K. Y., Katschke, K. J., Gorgani, N. N., Kljavin, N. M., Elliott, J. M., Diehl, L., Scales, S. J., Ghilardi, N., & van Lookeren Campagne, M. (2006) · Cell · doi:10.1016/j.cell.2005.12.039 · Cited by 628
Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000082g · Cited by 611
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P. (2020) · Polymers · doi:10.3390/polym12020298 · Cited by 668
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Wen, H., Jung, H., & Li, X. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9814-9 · Cited by 574
Chen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
PEGylated liposomes: immunological responses
Mohamed, M., Abu Lila, A. S., Shimizu, T., Alaaeldin, E., Hussein, A., Sarhan, H. A., Szebeni, J., & Ishida, T. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1627174 · Cited by 523
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
Stealth Coating of Nanoparticles in Drug-Delivery Systems
Fam, S. Y., Chee, C. F., Yong, C. Y., Ho, K. L., Mariatulqabtiah, A. R., & Tan, W. S. (2020) · Nanomaterials · doi:10.3390/nano10040787 · Cited by 422
Rasines Mazo, A., Allison-Logan, S., Karimi, F., Chan, N. J.-A., Qiu, W., Duan, W., O’Brien-Simpson, N. M., & Qiao, G. G. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00738e · Cited by 329
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
The Biomolecular Corona of Lipid Nanoparticles for Gene Therapy
Francia, V., Schiffelers, R. M., Cullis, P. R., & Witzigmann, D. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00366 · Cited by 299
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Stealth Effect of Biomolecular Corona on Nanoparticle Uptake by Immune Cells
Caracciolo, G., Palchetti, S., Colapicchioni, V., Digiacomo, L., Pozzi, D., Capriotti, A. L., La Barbera, G., & Laganà, A. (2015) · Langmuir · doi:10.1021/acs.langmuir.5b02158 · Cited by 131
Clinically approved liposomal nanomedicines: lessons learned from the biomolecular corona
Caracciolo, G. (2018) · Nanoscale · doi:10.1039/c7nr07450f · Cited by 106
Nanoparticle impact on innate immune cell pattern-recognition receptors and inflammasomes activation
Silva, A. L., Peres, C., Conniot, J., Matos, A. I., Moura, L., Carreira, B., Sainz, V., Scomparin, A., Satchi-Fainaro, R., Préat, V., et al. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.09.003 · Cited by 95
Montano, D. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.756633 · Cited by 70
Metadata
- Authors
- Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 19
- Issue
- 12
- Pages
- 1945-1952
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W2056609366
- Cited by
- 267
- References
- 69
- FWCI
- 13.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.